831 completed, 200 unknown, 147 terminated, 132 recruiting. 645 Phase 2, 382 Phase 3, 192 Phase 4, 179 Phase 1, 95 Not applicable.
Follow Methotrexate: new trials by email Literature Review of Methotrexate trials Research Report on Methotrexate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis Dapagliflozin, Empagliflozin, Methotrexate - Rheumatoid Arthritis (RA) | Phase 2 | Not yet recruiting | Al-Azhar University | 90 | 2026-12-01 | 2026-10-08 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma Arsenic Trioxide (ATO), ETOPOSIDE - Study, Cisplatin - Medulloblastoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 78 | 2026-10-01 | 2026-10-02 |
| Treatment Strategy for Patients With RA-ILD Tocilizumab, Rituximab (RTX), Methotrexate - Rheumatoid Arthritis Associated Interstitial Lung Disease | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 204 | 2026-09-20 | 2026-09-03 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| The Effect of Nicorandil on Rheumatoid Arthritis Patients Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 70 | 2026-09-06 | 2026-09-16 |
| The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma High-dose Methotrexate - Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults | Phase 2 | Recruiting | Wake Forest University Health Sciences | 46 | 2026-09-01 | 2026-10-13 |
| Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." Revumenib, Fludarabine, Cytarabine (Ara-C) - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2026-08-31 | 2026-07-22 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL GELAD regimen, MEDA regimen, LEAP regimen - Extranodal NK/T-cell Lymphoma | Phase 3 | Recruiting | Rong Tao | 150 | 2026-08-11 | 2026-08-13 |
| R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Penpulimab, Rituximab, Methotrexate - Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma | Not applicable | Not yet recruiting | WEI XU | 58 | 2026-08-01 | 2026-08-14 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia methotrexate, rituximab, bortezomib - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2026-07-29 | 2025-12-18 | |
| Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment Natrunix 400 mg, Placebo, Methotrexate (MTX) - Rheumatoid Arthritis | Phase 2 | Not yet recruiting | XBiotech, Inc. | 108 | 2026-07-15 | 2025-12-09 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
| Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis JAK inhibitor(tofacitinib/upadacitinib) as advised by the rheumatologist as add on to 25 mg methotrexate - Rheumatoid Arthritis (RA) | Phase 4 | Not yet recruiting | Sheikh Zayed Federal Postgraduate Medical Institute | 100 | 2026-07-05 | 2026-06-09 |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ou Bai, MD/PHD | 66 | 2026-06-16 | 2026-07-01 |
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-12 | 2026-06-11 |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Eflornithine, Topotecan, Cyclophosphamide - Osteosarcoma, Ewing Sarcoma | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 406 | 2026-06-05 | 2026-10-06 |
Showing 20 of 1452. Sign in to see all of them.
Arthritis, Rheumatoid (287) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (250) · Leukemia (186) · Lymphoma (137) · Leukemia, Myeloid, Acute (104) · Burkitt Lymphoma (92) · Myelodysplastic Syndromes (79) · Lymphoma, Non-Hodgkin (65) · Graft vs Host Disease (63) · Breast Neoplasms (60) · Lymphoma, Large B-Cell, Diffuse (60) · Leukemia, Lymphocytic, Chronic, B-Cell (49) · Hodgkin Disease (47) · Lymphoma, Mantle-Cell (47) · Leukemia, Myeloid, Accelerated Phase (45)
Children's Oncology Group (57) · M.D. Anderson Cancer Center (57) · National Cancer Institute (NCI) (49) · Hoffmann-La Roche (48) · Fred Hutchinson Cancer Center (43) · St. Jude Children's Research Hospital (38) · Memorial Sloan Kettering Cancer Center (22) · Dana-Farber Cancer Institute (20) · Bristol-Myers Squibb (19) · Alliance for Clinical Trials in Oncology (17) · Amgen (17) · Genentech, Inc. (15) · SWOG Cancer Research Network (14) · Pfizer (13) · Therapeutic Advances in Childhood Leukemia Consortium (13)
United States (700) · Canada (161) · China (151) · United Kingdom (120) · Germany (119) · Australia (117) · France (113) · Italy (103) · Spain (93) · Netherlands (78) · Poland (78) · Czechia (73) · Belgium (70) · Switzerland (63) · Mexico (61)
Elias Jabbour (8) · Sima Jeha, MD (7) · Tanya Trippett, MD (5) · Dieter Hoelzer, MD,PhD (4) · H. Joachim Deeg, MD (4)
PMID 41671463, PMID 27338778, PMID 29244149, PMID 30649524, PMID 31401903, PMID 35622074, PMID 39121442, PMID 36526796, PMID 36931693, PMID 22491018, PMID 24498318, PMID 29463520, PMID 32816215, PMID 34706874, PMID 34870800, PMID 36600185, PMID 36601090, PMID 37890117, PMID 38446568, PMID 39192350, PMID 23007406, PMID 24429164, PMID 24970932, PMID 30842122, PMID 33127856, PMID 33242441, PMID 34048072, PMID 34519964, PMID 38958913, PMID 40908865, PMID 16105981, PMID 16421426, PMID 18050221, PMID 19144982, PMID 19433688, PMID 19546402, PMID 19667400, PMID 19767089, PMID 20154213, PMID 20661232, PMID 20970380, PMID 21719599, PMID 21994233, PMID 22127691, PMID 22150039, PMID 22228634, PMID 22442346, PMID 22493293, PMID 22966847, PMID 23024237
U10CA098543 (31), U10CA180886 (27), U10CA031946 (16), U10CA032102 (13), 2009 (11), 2015 (11), 2005 (10), P30CA016672 (10), 2016 (9), P30CA015704 (9), 2008 (8), 2014 (8), U10CA180821 (7), 2017 (6), 2023 (5)